×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NAMS – newamsterdam pharma company n.v. - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NAMS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/16
09:08 am
nams
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg
Medium
Report
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg
12/16
08:43 am
nams
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg
Low
Report
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg
12/16
08:40 am
nams
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg
Low
Report
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg
12/13
05:20 pm
nams
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]
Medium
Report
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]
12/13
05:16 pm
nams
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Low
Report
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
12/11
09:41 pm
nams
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants [Yahoo! Finance]
Low
Report
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants [Yahoo! Finance]
12/11
09:37 pm
nams
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Low
Report
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
12/11
11:12 am
nams
NewAmsterdam Pharma (NASDAQ: NAMS) had its price target raised by analysts at Scotiabank from $35.00 to $47.00. They now have a "sector outperform" rating on the stock.
Medium
Report
NewAmsterdam Pharma (NASDAQ: NAMS) had its price target raised by analysts at Scotiabank from $35.00 to $47.00. They now have a "sector outperform" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/20
04:26 pm
nams
Form 4 NewAmsterdam Pharma Co For: Dec 18 Filed by: Forbion Growth Management B.V.
Low
Report
Form 4 NewAmsterdam Pharma Co For: Dec 18 Filed by: Forbion Growth Management B.V.
12/18
04:15 pm
nams
Form 4 NewAmsterdam Pharma Co For: Dec 16 Filed by: Forbion Growth Management B.V.
Medium
Report
Form 4 NewAmsterdam Pharma Co For: Dec 16 Filed by: Forbion Growth Management B.V.
12/17
05:35 pm
nams
Form SC 13D/A NewAmsterdam Pharma Co Filed by: BCLS II Investco, LP
Low
Report
Form SC 13D/A NewAmsterdam Pharma Co Filed by: BCLS II Investco, LP
12/17
05:06 pm
nams
Form 4 NewAmsterdam Pharma Co For: Dec 13 Filed by: BCLS Fund III Investments GP, LLC
Medium
Report
Form 4 NewAmsterdam Pharma Co For: Dec 13 Filed by: BCLS Fund III Investments GP, LLC
12/17
04:01 pm
nams
Form SC 13D/A NewAmsterdam Pharma Co Filed by: Forbion Capital Fund IV Cooperatief U.A.
Low
Report
Form SC 13D/A NewAmsterdam Pharma Co Filed by: Forbion Capital Fund IV Cooperatief U.A.
12/17
10:29 am
nams
Form SC 13D/A NewAmsterdam Pharma Co Filed by: Frazier Life Sciences X, L.P.
Medium
Report
Form SC 13D/A NewAmsterdam Pharma Co Filed by: Frazier Life Sciences X, L.P.
12/16
04:15 pm
nams
Form 4 NewAmsterdam Pharma Co For: Dec 12 Filed by: Forbion Growth Management B.V.
Medium
Report
Form 4 NewAmsterdam Pharma Co For: Dec 12 Filed by: Forbion Growth Management B.V.
12/13
08:29 am
nams
Form 8-K NewAmsterdam Pharma Co For: Dec 11
Low
Report
Form 8-K NewAmsterdam Pharma Co For: Dec 11
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: